Your browser doesn't support javascript.
loading
Comparison of predictive value of risk scores for gastrointestinal bleeding in antiplatelet therapy.
Lv, Mei-Na; Zheng, Xiao-Chun; Jiang, Shao-Jun; Zhang, Hong-Qin; Xu, Fang-Da; Wu, Ting-Ting; Chen, Wen-Jun; Zhang, Jin-Hua.
Afiliação
  • Lv MN; Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
  • Zheng XC; College of Pharmacy, Fujian Medical University, Fuzhou, China.
  • Jiang SJ; College of Pharmacy, Fujian Medical University, Fuzhou, China.
  • Zhang HQ; Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
  • Xu FD; College of Pharmacy, Fujian Medical University, Fuzhou, China.
  • Wu TT; Department of Pharmacy, Fuzhou Second Hospital Affiliated to Xiamen University, Fuzhou, China.
  • Chen WJ; Department of Information, Fujian Medical University Union Hospital, Fuzhou, China.
  • Zhang JH; Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
Platelets ; 33(4): 586-591, 2022 May 19.
Article em En | MEDLINE | ID: mdl-34348065
ABSTRACT
Gastrointestinal bleeding (GIB) is the most common serious bleeding complication of antiplatelet therapy. The bleeding risk score (BRS) of GIB may help to determine the risk of bleeding, and provides a reference for the formulation of antiplatelet therapy regimen in clinical practice, but we found that no specific risk scores are available in East Asian patients. This study analyzed patients who were administered antiplatelet therapy from May 2015 to December 2018 in two medical centers. Patient's baseline data were obtained. We assessed four BRSs (New Score, RIETE Score, Cuschieri Score, de Groot Score) and compared them using the area under the receiver operating characteristic curve (AUC). The 4,052 patients enrolled in this study had an average age of 69.6 ± 10.8 years, and 65.9% of them were male. Among the 4,052 patients included, 171 patients experienced GIB within 6 months of follow-up. In the study population, the AUCs for the New, RIETE, Cuschieri, and de Groot scores were 0.673 (95% confidence interval (CI) 0.616-0.729, P < .001), 0.742 (95% CI 0.690-0.794, P < .001), 0.598 (95% CI 0.537-0.659, P = .002), and 0.875 (95% CI 0.839-0.912, P < .001), respectively. After validation, the de Groot Score has better performance. Among the four scores, the de Groot Score might be more suitable for helping Chinese clinicians to predict the risk of GIB in patients taking antiplatelet drugs, and reduce GIB events.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Inibidores da Agregação Plaquetária / Hemorragia Gastrointestinal Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Platelets Assunto da revista: HEMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Inibidores da Agregação Plaquetária / Hemorragia Gastrointestinal Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Platelets Assunto da revista: HEMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China